• Explore /
  • Poster
  • / Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.

Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.

Abstract Poster

Authors

null

Elias Jabbour

The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour , Anjali S. Advani , Matthias Stelljes , Wendy Stock , Michaela Liedtke , Nicola Gökbuget , Giovanni Martinelli , Susan Mary O'Brien , Kongming Wang , Tao Wang , M. Luisa Paccagnella , Barbara Sleight , Erik Vandendries , Daniel J. DeAngelo , Hagop M Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01564784

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7029)

DOI

10.1200/JCO.2016.34.15_suppl.7029

Abstract #

7029

Poster Bd #

21

Abstract Disclosures

Similar Posters

First Author: Daniel J. DeAngelo

First Author: Bei Hu

First Author: Saad Zafar Usmani

First Author: Ryan Daniel Cassaday